Objective: To review the pharmacology, efficacy, and safety of obeticholic acid (OCA) and determine its clinical role relative to other agents in the treatment of patients with primary biliary cholangitis (PBC). Data Sources: A PubMed search (1946 to November 2016) was conducted using the terms INT-747, obeticholic acid, OCA, farnesoid X receptor agonists, FXR agonists, primary biliary cirrhosis, and primary biliary cholangitis. Study Selection and Data Extraction: Phase II and III studies evaluating the use of OCA in PBC patients were included in this review. Data Synthesis: OCA, a farnesoid X receptor (FXR) agonist, is indicated for adult patients with PBC in combination with ursodeoxycholic acid (UDCA) or as monotherapy if unable to tolerate UDCA. Two clinical trials were identified evaluating OCA for the treatment of PBC. Study end points utilized biochemical markers (alkaline phosphatase [ALP] and bilirubin). A phase II study (n = 165) to determine efficacy and safety of OCA at 3 different doses (10 mg, 25 mg, 50 mg) demonstrated statistically significant reductions in ALP (P < .0001 for all OCA groups versus placebo) after 12 weeks. A phase III trial (n = 217) assessed lower OCA doses (5 mg and 10 mg) with a longer study duration (12 months). Statistically significant differences (P < .001) between the 5 to 10 mg group (46%) and the 10 mg group (47%) compared to the placebo group (10%) were found. The primary adverse effect reported in both trials was pruritus. Conclusions: OCA is the first FXR agonist approved for the treatment of PBC. Ongoing research to evaluate clinical outcomes with OCA is currently underway.
GershwinMESelmiCWormanHJ. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194-1202.
7.
ParesACaballeriaLRodesJ.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715-720. doi:10.1053/j.gastro.2005.12.029.
TrivediPJHirschfieldGMGershwinME.Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Rev Clin Pharmacol. 2016;9:13-26. doi:10.1586/17512433.2015.1092381.
12.
PurohitTCappellMS.Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy. World J Hepatol. 2015;7:926-941. doi:10.4254/wjh.v7.i7.926.
13.
SclairSNLittleELevyC.Current concepts in primary biliary cirrhosis and primary sclerosing cholangitis. Clin Transl Gastroenterol. 2015;6:e109. doi:10.1038/ctg.2015.33.
14.
AliAHCareyEJLindorKD.Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. doi:10.3978/j.issn.2305-5839.2014.12.06.
15.
Obeticholic acid (Ocaliva) [Package insert]. New York, NY: Intercept Pharmaceuticals; 2016May. https://ocaliva.com/ocaliva_pi.pdf. Accessed September 1, 2016.
16.
HirschfieldGMMasonALuketicV. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751-761.e8. doi:10.1053/j.gastro.2014.12.005.
17.
NevensFAndreonePMazzellaG. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631-643. doi:10.1056/nejmoa1509840.
18.
JacobyARannardABuckD. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54:1622-1629. doi:10.1136/gut.2005.065862.
19.
Intercept Pharmaceuticals. Phase 3 study of obeticholic acid evaluating clinical outcomes in patients with primary biliary cirrhosis (ClinicalTrial.gov identifier: NCT02308111). https://clinicaltrials.gov/ct2/show/NCT02308111. Accessed August 31, 2016.
20.
LindorKDGershwinMEPouponRKaplanMBergasaNVHeathcoteEJ.American Association for the Study of Liver Diseases Practice Guidelines: primary biliary cirrhosis:Hepatology. 2009;50:291-308.
21.
AliAHLindorKD.Obeticholic acid for the treatment of primary biliary cholangitis. Expert Opin Pharmacother. 2016;17:1809-1815. doi:10.1080/14656566.2016.1218471.
